Mustafa Abu Salim
Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait.
Vaccines (Basel). 2021 Jan 7;9(1):27. doi: 10.3390/vaccines9010027.
The 6 kDa early secreted antigen target (ESAT6) is a low molecular weight and highly immunogenic protein of with relevance in the diagnosis of tuberculosis and subunit vaccine development. The gene encoding the ESAT6 protein is located in the -specific genomic region known as the region of difference (RD)1. There are 11 -specific RDs absent in all of the vaccine strains of BCG, and three of them (RD1, RD7, and RD9) encode immunodominant proteins. Each of these RDs has genes for a pair of ESAT6-like proteins. The immunological characterizations of all the possible proteins encoded by genes in RD1, RD7 and RD9 have shown that, besides ESAT-6 like proteins, several other proteins are major antigens useful for the development of subunit vaccines to substitute or supplement BCG. Furthermore, some of these proteins may replace the purified protein derivative of in the specific diagnosis of tuberculosis by using interferon-gamma release assays and/or tuberculin-type skin tests. At least three subunit vaccine candidates containing ESAT6-like proteins as antigen components of multimeric proteins have shown efficacy in phase 1 and phase II clinical trials in humans.
6 kDa早期分泌抗原靶点(ESAT6)是一种低分子量且具有高度免疫原性的蛋白质,与结核病的诊断及亚单位疫苗研发相关。编码ESAT6蛋白的基因位于特定的基因组区域,即差异区域(RD)1。在所有卡介苗疫苗株中均不存在11个特定的RDs,其中三个(RD1、RD7和RD9)编码免疫显性蛋白。这些RDs中的每一个都有一对ESAT6样蛋白的基因。对RD1、RD7和RD9中基因所编码的所有可能蛋白质的免疫学特性研究表明,除了ESAT-6样蛋白外,其他几种蛋白质也是用于开发替代或补充卡介苗的亚单位疫苗的主要抗原。此外,其中一些蛋白质可通过干扰素-γ释放试验和/或结核菌素型皮肤试验,在结核病的特异性诊断中替代结核菌素纯蛋白衍生物。至少有三种含有ESAT6样蛋白作为多聚体蛋白抗原成分的亚单位疫苗候选物,已在人体的I期和II期临床试验中显示出疗效。